Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
46
resultados
Última actualización
21/05/2025 [07:36:00]
Resumen de: WO2025099460A1
The invention relates to calibration standards for use in a single-molecular detection methods, in particular to quantify protein complexes in a sample.
Resumen de: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Resumen de: WO2025099458A1
The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.
Resumen de: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Resumen de: WO2025094139A1
This application is directed to detecting presence or quantity of at least two different molecules. A sensor includes a plurality of chambers, a nanowell array electrode, and a circuit board platform. The sensor separates, cleaves, filters, and detects the at least two different molecules selected from the group consisting of Aβ peptides and tau-protein from a sample in the plurality of nanowells. In some embodiments, the presence or quantity of at least three different Aβ peptides is detected, and an effective amount of a therapeutic compound is administrated to treat Alzheimer in a subject in need thereof.
Resumen de: US2025147041A1
Methods for the detection or quantitation of amyloid beta include detecting amyloid beta or fragments thereof by mass spectrometry. The methods may also include determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). Such methods may include the diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: WO2025095508A1
The present invention relates to a biohybrid robot including an eye/brain organoid, a motor nerve spheroid, and a muscle bundle, and a manufacturing method therefor. The universal biohybrid robot according to the present invention can generate movement of muscle cells by an electrophysiological signal generated in the eye/brain organoid like a human motor system by using light stimulation and a neurotransmitter. It is expected that the present invention can be used in a disease model simulating a signal transmission system of the human body by combining various neurodegenerative diseases, such as Parkinson and Alzheimer's disease models, and eye tumor models in the future, and can be used to manufacture a drug screening platform that leverages the movement of biohybrid robots composed of living tissues.
Resumen de: WO2025093893A1
The present invention relates to methods of measuring the presence and/or levels of a combination of five biomarkers in a sample, said biomarkers being neurofilament light (NfL) polypeptide, glial fibrillary acidic protein (GFAP), β-Amyloid 1-42 (Aβ1-42), β-Amyloid 1-40 (Aβ1-40), and phosphorylated Tau (p-Tau181, pTau-231 and/or p-Tau217). The methods can be used to predict the subject's risk or likelihood of having and/or developing Alzheimer's disease, thus also provided is a method of predicting a subject's risk or likelihood of having and/or developing Alzheimer's disease, said method comprising measuring the presence of and/or the levels of the combination of five biomarkers. Further provided is a method of prognosing or diagnosing Alzheimer's disease in a subject comprising the methods of measuring the presence of and/or the levels of the combination of five biomarkers, and a method of treating Alzheimer's disease comprising predicting a subject's risk or likelihood of developing or having Alzheimer's disease using the methods of measuring the presence and/or levels of the combination of five biomarkers and administering a treatment if the risk or likelihood exceeds a threshold value.
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Resumen de: US2025145722A1
Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Resumen de: US2025147049A1
The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.
Resumen de: EP4549585A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Resumen de: EP4548992A2
Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: AU2023357033A1
The present disclosure generally relates to the surprising discovery that subjects likely to respond to treatment with an 11β-HSD1 inhibitor can be selected for treatment based on a comparison between a baseline level of a tau protein in the subject, and a reference level of the tau protein.
Resumen de: WO2025090763A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Resumen de: AU2023406056A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: WO2024240079A1
The present invention relates to the technical field of medicines. Disclosed are a detection marker, a diagnostic marker, a use thereof, and a kit. In the present invention, PPP2R5C is used as a detection marker for the preclinical stage of Alzheimer's disease (AD) and as a diagnostic marker for mild cognitive impairment and AD; thus, the problems of detection defects and lack of effective blood biomarkers in lumbar puncture and PET-CT detection methods used in early diagnosis of AD are solved.
Resumen de: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: US2025130246A1
The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: AU2023294616A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: WO2025080894A1
In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).
Resumen de: US2025122570A1
Methods are provided for identifying Alzheimer's disease cells or subjects, based on the methylation status of multiple methylation markers in genomic DNA. Also provided are methods for identifying therapeutic agents for treating Alzheimer's disease by monitoring changes in the methylation status of multiple methylation markers.
Resumen de: US2025123297A1
Disclosed herein is a newly identified secreted nanoparticle that is morphologically and molecularly distinct from the recently described nanoparticle termed an exomere. The disclosed nanoparticle is referred to herein as a supermere. Both exomeres and supermeres are amembranous in contrast to membrane-enclosed extracellular vesicles (EVs). Supermeres are smaller and morphologically distinct from exomeres. These supermeres contain cargo with diagnostic and therapeutic applications.
Nº publicación: US2025123296A1 17/04/2025
Solicitante:
SHIMADZU CORP [JP]
THE UNIV OF TOKYO [JP]
Shimadzu Corporation,
The University of Tokyo
Resumen de: US2025123296A1
A level of mouse Aβ1-40 and a level of mouse APP669-711 in a biological sample derived from an AD model mouse are measured by detection of markers including mouse Aβ1-40 and mouse APP669-711; an APP669-711/Aβ1-40 ratio which is a ratio of the level of mouse APP669-711 to the level of mouse Aβ1-40 is calculated; and when the ratio in the AD model mouse is higher than the same ratio in a reference mouse in which cerebral Aβ deposition is absent, it is judged that an amount of cerebral Aβ deposition in the AD model mouse is higher than an amount of cerebral Aβ deposition in the reference mouse.
BOPI
Sede Electrónica
